Use Of Hep C Rx Down 40 Percent Among Medicaid Beneficiaries In 2015

By John Wilkerson / September 26, 2016 at 6:05 PM
Usage of hepatitis C drugs dropped 40 percent among Medicaid patients in 2015, according to pharmacy benefit manager Express Scripts, and most of that drop occurred in states that cover the drugs in fee-for-service Medicaid instead of letting private plans manage the drugs. There was no competition for Gilead Sciences’ hepatitis C medications -- Sovaldi and Harvoni -- during their first year on the market, and the price of the drug Sovaldi sparked a debate over drug prices that continues...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.